9 Specific Facts About HRT and Bone Density That Go Beyond the Basic 'It Helps' Message
Bone loss was the last thing on my mind when hot flushes started — it felt too distant, too invisible to worry about. But the research on how fast bone density can fall in the first years after periods stop genuinely changed how I thought about the whole conversation around HRT. It stopped feeling like a quality-of-life debate and started feeling like a long-term health decision that deserved a lot more attention.
Learn more about Rose →Bone loss accelerates fastest in the two to three years immediately after the final period
Oestrogen plays a direct role in slowing the activity of osteoclasts — the cells responsible for breaking down bone tissue. When oestrogen drops sharply at menopause, osteoclast activity surges, and women can lose between one and three percent of bone density per year during this early window, compared to the much slower age-related loss seen before menopause. This is why the timing of any intervention matters so much: the rate of loss is not linear, and the early years represent the steepest part of the curve.
Starting HRT within five years of menopause produces measurably greater bone protection than starting later
The 'window of opportunity' concept applies to bones just as it does to cardiovascular health — starting oestrogen therapy earlier in the menopause transition preserves more existing bone mass because there is more to preserve. Studies including data from the Women's Health Initiative show that women who began HRT close to menopause had significantly better bone mineral density outcomes than those who started a decade or more later. Starting late still offers some benefit, but the protective effect on bone microstructure that has already deteriorated is limited.
Standard HRT doses reduce hip fracture risk by approximately one third in healthy postmenopausal women
The Women's Health Initiative trial, despite its well-documented controversies, did produce clear evidence that combined oestrogen-progestogen therapy reduced hip fracture risk by around 34 percent and overall fracture risk by 24 percent compared to placebo. Hip fractures are the most clinically serious consequence of osteoporosis, carrying significant mortality risk in older women, so this reduction is not trivial. This finding has been replicated across multiple large observational studies, making the bone-protective effect one of the most consistently evidenced benefits of HRT.
The bone benefits disappear relatively quickly once HRT is stopped
HRT suppresses bone resorption while it is being taken, but it does not permanently reset bone metabolism — once oestrogen is withdrawn, the accelerated loss associated with low oestrogen resumes. Research suggests that women who stop HRT experience a period of catch-up bone loss, and that within a few years of stopping, their fracture risk returns toward levels comparable to women who never took HRT. This does not mean HRT must be taken indefinitely, but it does mean the duration decision is genuinely relevant to fracture outcomes, not just symptom management.
Transdermal oestrogen appears to provide equivalent bone protection to oral oestrogen at comparable doses
Head-to-head comparisons of oral versus transdermal (patch, gel, spray) oestrogen show similar effects on bone mineral density when doses are matched, which matters because route affects other aspects of safety — particularly clotting risk — differently. Transdermal delivery bypasses first-pass liver metabolism, which is why it carries a lower venous thromboembolism risk than oral forms; the good news is that women who prefer or are recommended transdermal HRT for safety reasons do not appear to sacrifice bone protection in the trade-off. This makes route of delivery a decision that can be driven by individual cardiovascular or clotting risk without compromising skeletal outcomes.
Lower doses of oestrogen still offer meaningful bone protection, though the effect is dose-dependent
Not every woman is prescribed — or comfortable taking — a standard dose of oestrogen, and the evidence suggests that lower doses do still reduce bone turnover markers and preserve density, just to a somewhat lesser degree. Studies on ultra-low-dose transdermal oestradiol have shown statistically significant improvements in lumbar spine and hip bone mineral density compared to placebo, even at doses well below those typically used for symptom relief. For women who cannot tolerate higher doses or have specific health considerations, this is clinically useful information rather than an all-or-nothing picture.
Testosterone does not appear to provide independent bone protection in women at standard therapeutic doses
While testosterone is increasingly prescribed for women during perimenopause and menopause — primarily for libido and energy — the evidence that it independently protects bone in the absence of adequate oestrogen is weak. Some studies suggest testosterone may contribute to bone density when used alongside oestrogen, but it is oestrogen that drives the primary protective mechanism, not androgens. Women taking testosterone-only or very low oestrogen alongside testosterone should not assume their bones are covered by the androgen alone.
Women with premature ovarian insufficiency face a significantly higher long-term fracture risk if HRT is not used until at least the natural age of menopause
For women whose ovaries stop functioning before age 40 — whether through POI, surgical menopause, or cancer treatment — the extended years of oestrogen deficiency create a substantially greater cumulative bone loss than natural menopause at 51. Guidelines from endocrinology and gynaecology bodies consistently recommend that women with POI use HRT until at least the average age of natural menopause, specifically to protect bone (and cardiovascular) health, not just for symptom control. The fracture risk in untreated POI is not a distant theoretical concern — it is measurably elevated by midlife.
HRT and bisphosphonates can be used together, and the combination may offer greater bone protection than either alone
Bisphosphonates — medications like alendronate that directly inhibit osteoclast activity — work through a different mechanism than oestrogen, which means combining them with HRT is physiologically rational rather than redundant. Small studies have shown additive effects on bone mineral density when both are used, and for women with established osteoporosis or very high fracture risk who are also experiencing significant menopause symptoms, this combination can address both problems simultaneously. A bone specialist and a menopause specialist should ideally both be involved in this kind of decision, as it requires weighing the evidence carefully for the individual's full health picture.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.